KONINKLIJKE PHILIPS NV (PHIA.AS) Stock Fundamental Analysis
AMS:PHIA - Euronext Amsterdam - NL0000009538 - Common Stock - Currency: EUR
Overall PHIA gets a fundamental rating of 2 out of 10. We evaluated PHIA against 63 industry peers in the Health Care Equipment & Supplies industry. PHIA has a bad profitability rating. Also its financial health evaluation is rather negative. PHIA has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
PHIA had positive earnings in the past year.
The reported net income has been mixed in the past 5 years: PHIA reported negative net income in multiple years.
PHIA had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
With a Return On Assets value of 1.37%, PHIA perfoms like the industry average, outperforming 41.27% of the companies in the same industry.
PHIA's Return On Equity of 3.19% is in line compared to the rest of the industry. PHIA outperforms 41.27% of its industry peers.
PHIA has a Return On Invested Capital of 3.56%. This is comparable to the rest of the industry: PHIA outperforms 41.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.37% | ||
| ROE | 3.19% | ||
| ROIC | 3.56% |
ROA(3y)-3.08%
ROA(5y)1.15%
ROE(3y)-7.29%
ROE(5y)2.23%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Profit Margin value of 2.07%, PHIA perfoms like the industry average, outperforming 44.44% of the companies in the same industry.
PHIA has a worse Operating Margin (5.39%) than 61.90% of its industry peers.
PHIA's Operating Margin has declined in the last couple of years.
The Gross Margin of PHIA (43.42%) is worse than 71.43% of its industry peers.
PHIA's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.39% | ||
| PM (TTM) | 2.07% | ||
| GM | 43.42% |
OM growth 3Y-2.25%
OM growth 5Y-8.45%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.71%
GM growth 5Y1.08%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PHIA is destroying value.
The number of shares outstanding for PHIA has been reduced compared to 1 year ago.
PHIA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, PHIA has a worse debt to assets ratio.
2.2 Solvency
PHIA has an Altman-Z score of 1.79. This is a bad value and indicates that PHIA is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of PHIA (1.79) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.60 indicates that PHIA is somewhat dependend on debt financing.
PHIA has a worse Debt to Equity ratio (0.60) than 68.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.6 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.79 |
ROIC/WACC0.56
WACC6.31%
2.3 Liquidity
A Current Ratio of 1.28 indicates that PHIA should not have too much problems paying its short term obligations.
PHIA has a Current ratio of 1.28. This is in the lower half of the industry: PHIA underperforms 60.32% of its industry peers.
PHIA has a Quick Ratio of 1.28. This is a bad value and indicates that PHIA is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.79, PHIA is not doing good in the industry: 65.08% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.28 | ||
| Quick Ratio | 0.79 |
3. Growth
3.1 Past
PHIA shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.45%.
Measured over the past years, PHIA shows a decrease in Earnings Per Share. The EPS has been decreasing by -7.17% on average per year.
PHIA shows a decrease in Revenue. In the last year, the revenue decreased by -0.89%.
The Revenue has been growing slightly by 1.00% on average over the past years.
EPS 1Y (TTM)7.45%
EPS 3Y-5.66%
EPS 5Y-7.17%
EPS Q2Q%-3.85%
Revenue 1Y (TTM)-0.89%
Revenue growth 3Y1.65%
Revenue growth 5Y1%
Sales Q2Q%-0.99%
3.2 Future
Based on estimates for the next years, PHIA will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.99% on average per year.
The Revenue is expected to grow by 3.55% on average over the next years.
EPS Next Y9.94%
EPS Next 2Y11.54%
EPS Next 3Y12.13%
EPS Next 5Y12.99%
Revenue Next Year1.15%
Revenue Next 2Y2.61%
Revenue Next 3Y3.12%
Revenue Next 5Y3.55%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 14.41, the valuation of PHIA can be described as correct.
90.48% of the companies in the same industry are more expensive than PHIA, based on the Price/Earnings ratio.
PHIA is valuated rather cheaply when we compare the Price/Earnings ratio to 26.29, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 11.53, the valuation of PHIA can be described as reasonable.
Based on the Price/Forward Earnings ratio, PHIA is valued cheaper than 82.54% of the companies in the same industry.
PHIA is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.17, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.41 | ||
| Fwd PE | 11.53 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PHIA is valued cheaply inside the industry as 82.54% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 10.77 |
4.3 Compensation for Growth
PHIA's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as PHIA's earnings are expected to grow with 12.13% in the coming years.
PEG (NY)1.45
PEG (5Y)N/A
EPS Next 2Y11.54%
EPS Next 3Y12.13%
5. Dividend
5.1 Amount
PHIA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AMS:PHIA (6/2/2025, 7:00:00 PM)
19.88
-0.37 (-1.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners48.26%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap18.69B
Analysts73.08
Price Target28.45 (43.11%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)-70.49%
DP0.27%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.14%
Min EPS beat(2)-11.97%
Max EPS beat(2)22.24%
EPS beat(4)1
Avg EPS beat(4)-3.31%
Min EPS beat(4)-16.56%
Max EPS beat(4)22.24%
EPS beat(8)2
Avg EPS beat(8)-6.4%
EPS beat(12)4
Avg EPS beat(12)8.51%
EPS beat(16)5
Avg EPS beat(16)1.66%
Revenue beat(2)0
Avg Revenue beat(2)-2.5%
Min Revenue beat(2)-3.04%
Max Revenue beat(2)-1.96%
Revenue beat(4)0
Avg Revenue beat(4)-3.17%
Min Revenue beat(4)-5.22%
Max Revenue beat(4)-1.96%
Revenue beat(8)0
Avg Revenue beat(8)-3.16%
Revenue beat(12)2
Avg Revenue beat(12)-1.77%
Revenue beat(16)2
Avg Revenue beat(16)-1.84%
PT rev (1m)-1.57%
PT rev (3m)-1.47%
EPS NQ rev (1m)-17.81%
EPS NQ rev (3m)-20.5%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.3%
Revenue NQ rev (1m)-3.15%
Revenue NQ rev (3m)-4.8%
Revenue NY rev (1m)-1.82%
Revenue NY rev (3m)-3.36%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.41 | ||
| Fwd PE | 11.53 | ||
| P/S | 1.04 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.6 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.77 |
EPS(TTM)1.38
EY6.94%
EPS(NY)1.72
Fwd EY8.67%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS19.13
BVpS12.44
TBVpS-1.36
PEG (NY)1.45
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.37% | ||
| ROE | 3.19% | ||
| ROCE | 4.75% | ||
| ROIC | 3.56% | ||
| ROICexc | 3.78% | ||
| ROICexgc | 11.65% | ||
| OM | 5.39% | ||
| PM (TTM) | 2.07% | ||
| GM | 43.42% | ||
| FCFM | N/A |
ROA(3y)-3.08%
ROA(5y)1.15%
ROE(3y)-7.29%
ROE(5y)2.23%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y9.87%
ROICexcg growth 5Y-2.9%
ROICexc growth 3Y4.04%
ROICexc growth 5Y-7.35%
OM growth 3Y-2.25%
OM growth 5Y-8.45%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.71%
GM growth 5Y1.08%
F-ScoreN/A
Asset Turnover0.66
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.6 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 2.99 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.28 | ||
| Quick Ratio | 0.79 | ||
| Altman-Z | 1.79 |
F-ScoreN/A
WACC6.31%
ROIC/WACC0.56
Cap/Depr(3y)50.01%
Cap/Depr(5y)53.78%
Cap/Sales(3y)3.94%
Cap/Sales(5y)4.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.45%
EPS 3Y-5.66%
EPS 5Y-7.17%
EPS Q2Q%-3.85%
EPS Next Y9.94%
EPS Next 2Y11.54%
EPS Next 3Y12.13%
EPS Next 5Y12.99%
Revenue 1Y (TTM)-0.89%
Revenue growth 3Y1.65%
Revenue growth 5Y1%
Sales Q2Q%-0.99%
Revenue Next Year1.15%
Revenue Next 2Y2.61%
Revenue Next 3Y3.12%
Revenue Next 5Y3.55%
EBIT growth 1Y379.25%
EBIT growth 3Y-0.63%
EBIT growth 5Y-7.54%
EBIT Next Year50.08%
EBIT Next 3Y20.59%
EBIT Next 5YN/A
FCF growth 1Y-45.51%
FCF growth 3Y-40.93%
FCF growth 5Y-1.73%
OCF growth 1Y-31.12%
OCF growth 3Y-32.38%
OCF growth 5Y-4.03%